GLP-1 receptor agonists for obesity treatment

Clinical MedicineUpdated Oct 5, 2026Version v1

Evidence

Public papers linked to this topic and used as evidence for gaps, timelines, and knowledge views.

359 papers

Showing 265-276 of total 359 evidence records.

Open a paper to inspect abstract, source links, and topic context.

2026PubMedDirectly related

Medication Safety and Perioperative Risk Management of GLP-1 Receptor Agonists: A Pharmacist-Led Framework for Individualized Care.

Shen N; Zhu C; Wang F; Wu M

Jan 1, 2026Therapeutics and clinical risk management

2026PubMedDirectly related

Glucagon-like Peptide-1 Receptor Agonists and Dual Incretin Therapies Across HFpEF and Cardiovascular Outcomes Trials in Patients with Obesity.

Belančić A; Klobučar S; Skroče K; Ciudin A; Borovac JA

Jan 1, 2026Medicina (Kaunas, Lithuania)

2026PubMedDirectly related

Multisystem Benefits of GLP-1 Microdosing: A Narrative Review.

Panlilio MA; Piserchio N; Hennessey M; Torres K; Khan S; Choy L

Jan 1, 2026Cureus

2026PubMedDirectly related

Incretin-based therapies in peri- and postmenopausal women with obesity: an expert position statement from the Spanish Menopause Society.

Sánchez-Prieto M; Romero-Domínguez M; Orozco R; Lilue M; Lubián-López DM; González SP; Nieto A; Coronado P; Sánchez-Borrego R; Cano A; Castelo-Branco C; Palacios S; Young Investigators Group of the Spanish Menopause Society (MenoYoung Spain)

Jan 1, 2026Maturitas

2026PubMedDirectly related

Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, and Atrial Fibrillation: An Umbrella Review With Methodological Appraisal of Overlapping Meta-Analyses.

Ramzy D; Isshak R; Patel D; Elmasry M; Shri N; Romero J; Paromita P; Nazmee T; Shamoon F

Jan 1, 2026Cureus

2026PubMedDirectly related

Medical nutrition therapy in incretin-treated obesity-related heart failure with preserved ejection fraction.

Ming Q; Li Z; Cui J

Jan 1, 2026Frontiers in nutrition

2026PubMedDirectly related

GLP-1 and GIP class drugs have neuroprotective properties in Alzheimer's and Parkinson's disease.

Hölscher C

Jan 1, 2026Frontiers in neuroscience

2026PubMedDirectly related

Mapping GLP-1 receptor agonist research across the MASLD-MASH-HCC continuum: a bibliometric and translational analysis.

Xie Y; Zhang X; Chen B

Jan 1, 2026Frontiers in medicine

2026PubMedSupporting evidence

Cardiovascular risk management in the elderly: a dilemma in daily clinical practice.

Dacquino GM; Galati G; Genovese L; Bravo FF; Bernardi M; Spadafora L; Pedretti RFE

Jan 1, 2026European journal of preventive cardiology

2026PubMedSupporting evidence

Causal Inference in Non-Allergic Asthma Associated with Obesity: Application of the Bradford Hill Viewpoints to a Complex Epidemiological Association.

Leija-Martinez JJ; Ensaldo-Carrasco E; Sánchez-Muñoz F; Del-Río-Navarro BE; Reyes-Noriega N; Huang F

Jan 1, 2026Epidemiologia (Basel, Switzerland)

2026PubMedDirectly related

Myoprotective Fat-Loss Phenotypes in Obesity-Associated Type 2 Diabetes: A 12-Month Real-World Cohort Study of Metformin-Based Treatment Regimens.

Bujdei-Tebeică I; Pantea-Stoian AM; Mihai DA; Ștefan SD; Serafinceanu C

Jan 1, 2026Clinics and practice

2026PubMedDirectly related

Real-World Evidence of the GLP-1RA/SGLT2-i Therapy versus Standard Care: A Retrospective Cohort Study.

Mahmoud NM; Hussein A; Mussa BM; Abusnana S

Jan 1, 2026Clinical medicine insights. Endocrinology and diabetes